WHO Raises Alert Over Acute Lack of Obesity Jabs

Fewer than one in 10 individuals who could benefit from GLP-1 drugs like Wegovy are able to get them, states the global health agency as it releases its inaugural guidance on the drugs.

Given over a billion individuals worldwide currently obese, it is calling for increased and just availability to these injectable treatments.

Based on estimates, in excess of 2,000,000,000 could be living with obesity by 2030 without intervention.

"The latest guidelines acknowledges that obesity is a long-term condition that can be addressed with comprehensive and ongoing treatment," stated the agency's head Tedros Adhanom Ghebreyesus.

Significant expense, limited production capacity, and logistical bottlenecks are significant obstacles to widespread availability to the injections that can assist patients in reducing considerable weight, explains the body.

Weight-Loss Drug Supply Crisis

Despite the present most optimistic outlook, the supply of such drugs could only cover around 100 million people – less than 10% of those who need them, per the health organization.

The recommendation encourages countries and companies to widen availability, via approaches such as voluntary licensing.

A patent on a key compound – the main ingredient of Novo Nordisk's Wegovy – is due to expire in multiple nations in 2026.

How Weight-Loss Jabs Operate

GLP-1 drugs mimick a natural hormone to slow digestion, suppress the appetite and increase satiety so individuals consume fewer calories.

People commonly begin shedding pounds in the initial weeks of starting on the once-weekly jabs.

Studies indicates users may see weight return a year later of discontinuing the drug, as their normal appetite return.

To be carrying excess weight increases your risk for developing diseases, like type 2 diabetes, cardiovascular issues, stroke, and some cancers.

Excess weight concerns individuals in every country and was linked to over three and a half million fatalities worldwide in 2024, as per the WHO.